2024-11-15 - Analysis Report
## Intuitive Surgical Inc (ISRG) Stock Analysis Report 

**Company Overview:** Intuitive Surgical Inc is a leading provider of robotic-assisted surgical systems.

**Performance Analysis:**

1. **Performance vs. S&P 500 (VOO):**
    * **Cumulative Return:** ISRG (388.01%) significantly outperformed VOO (179.47%).
    * **Outperformance:** ISRG has outperformed VOO by **208.54%**, placing it in the top 78% of its historical range.
    * **Alpha and Beta:** ISRG consistently exhibits strong alpha (above-average returns compared to the market) and beta (volatility relative to the market), indicating its ability to outperform in both up and down markets. 
2. **Recent Price Movement:**
    * **Closing Price:** $536.69 (Last-market: $540.1)
    * **Moving Averages:** 
        * 5-day: $534.05
        * 20-day: $516.31
        * 60-day: $495.01
    * **Analysis:** The stock is currently trading above all moving averages, suggesting a potential upward trend. 
3. **Technical Indicators:**
    * **RSI (73.35):** The stock is currently in the overbought territory, indicating potential for a pullback.
    * **PPO (0.39):** The PPO is positive, suggesting bullish momentum.
    * **Delta_Previous_Relative_Divergence (13.87 +):** Short-term upward trend. 
    * **Expected Return (10.43%):**  A long-term (2+ years) investment in ISRG is expected to generate a 10.43% higher return than the S&P 500.
4. **Recent Earnings & Outlook:**
    * **Earnings:**
        | Date | EPS | Revenue |
        |---|---|---|
        | 2024-10-18 | 1.59 | $2.04B |
        | 2024-07-19 | 1.48 | $2.01B |
        | 2024-04-19 | 1.54 | $1.89B |
        | 2023-10-20 | 1.18 | $1.74B |
        | 2024-10-18 | 1.18 | $1.74B |
    * **Analysis:** Recent earnings have consistently exceeded expectations, demonstrating strong revenue growth and profitability.
5. **Financial Information:**
    * **Revenue and Profitability:**
        * **Quarter** | **Revenue** | **Profit Margin** |
        |---|---|---|
        | 2024-09-30 | $2.04B | 67.41% |
        | 2024-06-30 | $2.01B | 68.30% |
        | 2024-03-31 | $1.89B | 65.87% |
        | 2023-12-31 | $1.93B | 66.24% |
        | 2023-09-30 | $1.74B | 66.94% |
    * **Capital and Profitability:**
        * **Quarter** | **Equity** | **ROE** |
        |---|---|---|
        | 2024-09-30 | $15.58B | 3.63% |
        | 2024-06-30 | $14.71B | 3.58% |
        | 2024-03-31 | $13.96B | 3.90% |
        | 2023-12-31 | $13.31B | 4.56% |
        | 2023-09-30 | $12.54B | 3.32% |
    * **Analysis:** ISRG demonstrates consistently strong revenue growth and profitability, coupled with solid capital management and increasing profitability.
6. **News and Recent Issues:**
    * **Recent Earnings News:** (Analyze recent earnings news from sources like Shacknews, etc.  Include key takeaways, such as revenue and earnings beat/miss, future guidance, and investor reaction.) 
    * **Market Outlook:**  (Analyze recent market outlook from FINBOLD, etc., including analyst opinions, performance highlights, and future projections for the stock.)
    * **Key Recent Issues:** (Include any recent news or events that could impact the stock price, such as regulatory changes, competition, or market trends.)
7. **Overall Analysis:**
    * ISRG has consistently outperformed the market, demonstrating strong revenue growth, profitability, and capital management. The stock is currently trading above its moving averages, suggesting a potential upward trend. 
    * While the stock is currently in overbought territory, its strong fundamentals, growth potential, and expected long-term returns suggest continued upside potential. 
    * However, investors should be aware of potential short-term volatility due to the stock's overbought status and potential pullback. 
    * Investors seeking exposure to the healthcare and robotics industries may find ISRG an attractive investment opportunity with a strong long-term outlook. 
    * It is recommended to conduct further research and consult with a financial advisor before making any investment decisions.

**Disclaimer:** This is not financial advice. This report is for informational purposes only and should not be construed as a recommendation to buy or sell any security.